A new clinical trial led by the Penn State College of Medicine–based Beat Childhood Cancer Research Consortium will evaluate whether the drug eflornithine (DFMO) can help prevent relapse and improve outcomes for patients with Ewing sarcoma and osteosarcoma — two aggressive bone cancers that have seen few meaningful treatment advances in decades, according to Giselle Saulnier Sholler, MD, MSc, chair and founder of the consortium. Read more: https://pennstatehealthnews.org/2026

Researchers at Cleveland Clinic Children’s have helped identify a previously unknown gene that increases the risk of developing osteosarcoma, the most common type of malignant bone tumor in children and young adults. Read more: https://newsroom.clevelandclinic.org/2025/10/09/new-research-reveals-genetic-link-to-most-common-pediatric-bone-cancer

Ewing’s sarcoma, osteosarcoma, and other bone cancers often impinge upon the growth plates of children’s arms and legs, explained...

Now, scientists at the University of British Columbia have identified a potential drug that could halt osteosarcoma's spread. In a study...

Scientists at St. Jude Children’s Research Hospital identified chemokines expressed by osteosarcoma that improved CAR T-cell homing, with...

A new drug that potentially works against all main types of primary bone cancer in children has been described by the scientists who...

New clinical guidelines enabling a better understanding of childhood bone cancer will revolutionise treatment for these young patients...

Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer....

Survivors of childhood osteosarcoma and Ewing sarcoma (EWS) have an elevated risk of neurocognitive impairment, according to study...

Researchers at the University of East Anglia and University of Manchester have made an important breakthrough that could lead to "kinder"...